Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.

Empagliflozin

SGLT2 Inhibitor2014
Drug ClassSGLT2 Inhibitor
Year Approved2014
Conditions TreatedType 2 diabetes, heart failure
AvailabilityPrescription

About Empagliflozin

A revolutionary SGLT2 inhibitor that lowers blood sugar by causing glucose excretion in urine. Empagliflozin or Jardiance was the first diabetes drug shown to reduce cardiovascular death. It also reduces heart failure hospitalizations and slows kidney disease progression. SGLT2 inhibitors work by blocking glucose reabsorption in the kidney. Side effects include genital yeast infections and rare diabetic ketoacidosis. Empagliflozin has transformed diabetes care by providing cardiovascular and kidney benefits beyond glucose control.

Related Medications